Therapeutic agents that can prevent Nodal/Cripto interaction and downstream signaling, such as neutralizing Nodal antibodies and ligand traps such as Lefty or Cerberus, have shown promising tumor-inhibiting potential in melanoma, breast, and pancreatic cancers [108,109,110]. This evidence concerns the gene CRIPTO and familial pancreatic carcinoma.